Page 55 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 3 ฉบับที่ 1

«“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë Û ©∫—∫∑’Ë Ò µÿ≈“§¡ ÚıÙ˜-¡°√“§¡ ÚıÙ¯ 53

µ“√“ß∑’Ë 8 º≈°“√µ√«®‡π◊ÈÕ‡¬◊ËÕÕ«—¬«–∑“ß®ÿ≈欓∏‘«‘∑¬“¢ÕßÀπŸ·√∑‡æ»‡¡’¬∑’ˉ¥â√—∫ “√ °—¥¬“·°â

°…—¬≈‘Èπ°√–∫◊Õ‡ªìπ‡«≈“ 3 ‡¥◊Õπ

¢π“¥¢Õß “√ °—¥¬“·°â°…—¬≈‘Èπ°√–∫◊Õ (°./°°./«—π)

Õ«—¬«– °“√‡ª≈’ˬπ·ª≈ß 0 0.5 2.5 5.0 5.0-R
n=15 n=15 n=15 n=15 n=15
ªÕ¥ Lymphoid proliferated 13/15 11/15 7/15* 11/15 7/15*
peribronchioles

µ—∫ Centrilobular fatty 0/15 0/15 1/15 0/15 0/15
degeneration (+1)
≈”‰ â‡≈Á° Lymphoid aggregated 3/15 3/15 0/15 0/15 2/15

≈”‰ â„À≠à in submucosa 4/15 5/15 2/15 3/15 1/15
µàÕ¡πÈ”≈“¬ Focal lymphocyte 0/15 0/15 1/15 0/15 0/15
adenitis

µ—«‡≈¢„πµ“√“ß· ¥ß„π√Ÿª¢Õß ®”π«πÀπŸ∑’˵√«®æ∫欓∏‘ ¿“æ / ®”π«πÀπŸ∑—ÈßÀ¡¥

* ·µ°µà“ß®“°°≈ÿࡧ«∫§ÿ¡Õ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘ ∑’Ë p<0.05
+1 À¡“¬∂÷ß °“√‡ª≈’ˬπ·ª≈ßæ∫‡æ’¬ß‡≈Á°πâÕ¬ (mild degree)

5.0-R=high recovery group

°√–∫◊Õ 1.67, 8.35, 16.7 °./°°./«—π ´÷Ëߧ‘¥‡ªìπ 1, 5 ·≈– 10 ‡∑à“¢Õߢπ“¥∑’Ë„™â„π§π‚¥¬ª√–¡“≥
‡π◊ËÕß®“° “√≈–≈“¬¢Õß “√ °—¥¢π“¥ Ÿß ÿ¥∑’Ë„Àâ·°àÀπŸ¡’§«“¡§«“¡‡¢â¡¢âπ§àÕπ¢â“ß ŸßÕ¬Ÿà·≈â«®÷߉¡à

“¡“√∂„Àâ “√ °—¥‰¥â¡“°°«à“ 10 ‡∑à“¢Õߢπ“¥∑’Ë„™â„π§π °“√√—∫ª√–∑“𬓷°â°…—¬≈‘Èπ°√–∫◊Õ„π
§π®–‡µ√’¬¡‚¥¬™—Ëßµ”√—∫¬“ 1 ™ÿ¥µâ¡‡Õ“πÈ”¥◊Ë¡ 𔬓™ÿ¥π’È°≈—∫¡“µâ¡∑ÿ°«—π·≈â«¥◊Ë¡®π§√∫ 7 «—π·≈â«
®÷ß√ÿ 1 «—π ¥—ßπ—È𧫓¡‡¢â¡¢âπ¢Õß à«π °—¥À√◊Õµ—«¬“ ”§—≠∑’ˉ¥â√—∫®÷ß≈¥≈߉ª∑ÿ°«—π ·µàÀπŸ∑¥≈Õß
‰¥â√—∫µ—«¬“ °—¥∑’ˇ¢â¡¢âπ§ß∑’Ë∑ÿ°«—π‡ªìπ‡«≈“µ‘¥µàÕ°—π 90 «—π

º≈°“√∑¥≈Õßæ‘…°÷Ë߇√◊ÈÕ√—ߧ√—Èßπ’È∫àß™’È«à“ “√ °—¥¢Õ߬“·°â°…—¬≈‘Èπ°√–∫◊Õ‰¡à¡’º≈µàÕ§à“
‡©≈’ˬπÈ”Àπ—°µ—« ª√‘¡“≥Õ“À“√∑’ËÀπŸ°‘π ÿ¢¿“æ∑—Ë«‰ª¢ÕßÀπŸ∑¥≈Õß Õ’°∑—È߉¡à∑”„ÀâπÈ”Àπ—°Õ«—¬«–
µà“ßʇª≈’ˬπ·ª≈߬°‡«âπÀπŸ‡æ»ºŸâ∑’ˉ¥â√—∫ “√ °—¥¢π“¥ Ÿß ÿ¥¡’πÈ”Àπ—° —¡æ—∑∏å¢Õß°√–‡æ“–Õ“À“√